danafarberbostonchildrens.org
Jun 23, 2025, 11:22
Riten Kumar Shared New ISTH Data: 3-Month Apixaban Course Shows Better Safety Profile Than Rivaroxaban in Acute VTE
Riten Kumar, Associate Professor of Pediatrics at Harvard, posted on X:
“Late breaking abstract at isth – 3 months of apixaban is safer than rivaroxaban for management of acute VTE!!!”
Be updated with Hemostasis Today.
-
Sep 1, 2026, 17:33Getnet Tarekegn: Comparing Oral Iron Preparations in Pediatric Iron Deficiency Anemia
-
Sep 1, 2026, 17:30Does Platelet FcγRIIA Really Amplify Thrombosis on Its Own? – RPTH Journal
-
Sep 1, 2026, 17:26EAHAD 2027 Abstract Submissions Are Now Open
-
Sep 1, 2026, 17:16Susan Shea։ VWF A1 Blockade Emerges as a Novel Strategy for Arterial Thrombosis
-
Sep 1, 2026, 17:04Hugo R Lara-Martinez: Recognizing HLH After Immune Checkpoint Inhibitor Therapy
-
Sep 1, 2026, 16:50Heghine Khachatryan: When to Test for Thrombophilia After VTE
-
Sep 1, 2026, 16:41Axel Diederichsen: Can Vitamin K2 and Vitamin D3 Slow the Progression of Severe Coronary Artery Calcification?
-
Sep 1, 2026, 16:15Sangeeta Pathak: The Bombay Blood Group as a Very Rare Phenotype
-
Sep 1, 2026, 16:14The Ecuador 2026 National Conference on Coagulation Disorders – WFH